Shots:
- AbCellera reported that a second Ab from its collaboration with Lilly, LY-CoV1404 has entered clinical trials in patients with mild-to-moderate COVID-19. The program will join Lilly’s ongoing Blaze-4 study where it will be evaluated as monothx. and in combination with other mAbs
- AbCellera unveils the preclinical data demonstrating LY-CoV1404 binds to a rarely mutated region of the SARS-CoV-2 spike protein and neutralizes all currently known variants of concern
- In Mar’2020, AbCellera initially mobilized its pandemic response platform and discover the first mAb therapy, bamlanivimab for COVID-19 which FDA has authorized for emergency use
Click here to read full press release/ article | Ref: Buisnesswire | Image: AbCellera
The post AbCellera to Initiate Clinical Trial of LY-CoV1404 Against Viral Variants of COVID 19 first appeared on PharmaShots.
